Recently, various executives have taken part in insider selling activity for the stocks of Facebook Inc (NASDAQ:FB), Exelixis, Inc. (NASDAQ:EXEL), Neuralstem, Inc.
Brean Capital’s healthcare analyst Jonathan Aschoff came out with a commentary on Neuralstem, Inc. (NASDAQ:CUR), after the company presented an updated analysis of its last completed NSI-566 Phase 1 …
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, …
Recently, various executives have taken part in insider selling activity for the stocks of Athersys, Inc.(NASDAQ:ATHX), Neuralstem, Inc.
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with some commentary on Neuralstem, Inc.(NASDAQ:CUR), after the biotech company released its second-quarter results and provided updates on its lead candidates.
Neuralstem, Inc (NASDAQ:CUR), a biopharmaceutical company developing neural stem cell-derived small molecule and cell therapy treatments for central nervous system diseases, reported its financial …
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system …
MLV analyst Raghuram Selvaraju came out with a research report today on Neuralstem, Inc. (NYSE MKT:CUR) in anticipation of several upcoming clinical catalysts for …
Neuralstem, Inc. (NYSEMKT:CUR) shares jumped over 8% in pre market trading to $2.
